Rachel Bluth, Kaiser Health News

Author's posts

Hidden Drugs And Danger Lurk In Over-The-Counter Supplements, Study Finds

Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.

White Coats As Superhero Capes: Med Students Swoop In To Save Health Care

Students from eight medical schools in and around New York City attended a conference Sept. 23 on progressive activism during their training years — and beyond.

Eat, Toke Or Vape: Teens Not Too Picky When It Comes To Pot’s Potpourri

State legalization efforts, as well as the introduction of edible or vaporized cannabis- infused products, may be contributing to experimentation by teens.

Senators Unveil Legislation To Protect Patients Against Surprise Medical Bills

The measure is designed to help people getting emergency care from hospitals or doctors that are not part of their insurance network.

Over Past 20 Years, The Percentage Of Children With ADHD Nearly Doubles

Researchers, using federal survey data, note a significant increase in diagnosis and also find a rise in the rates among girls and minorities.

Suicide By Opioid: New Research Suggests Overdoses Should Be Classified As Self-Harm

Researchers combined the number of suicide deaths with those associated with drug overdoses in an effort to better grasp the overlap between these two public health epidemics.

Financial Ties That Bind: Studies Often Fall Short On Conflict-Of-Interest Disclosures

A new study in JAMA Surgery finds that a large sample of published medical research failed to disclose details on the financial relationships between medical device makers and physicians. Changes in the disclosure process could close this loop.

To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream

The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.

Profiles For Sale: How Bits Of Captured Data Paint A Valuable Picture Of Your Health

Consumers, beware: Data brokers compile health and frailty profiles that have wide-ranging applications for drug companies, advertisers, insurers and other buyers.